
Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey
STAT Feature Article: By Eric Boodman
March 23, 2026

Advancing Care for Pediatric Patients with C. difficile: Insights from a Clinical Webinar on Investigational FMT
OpenBiome convened a live webinar featuring a distinguished panel of physicians from Boston Children’s Hospital, Texas Children’s Hospital, and the University of Minnesota. The discussion focused on the clinical management of pediatric patients with Clostridioides difficile (C. difficile) infection, with a particular emphasis on diagnostic considerations and the use of investigational fecal microbiota transplantation (FMT).

Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study
Studies of the microbes living on and in our bodies are conducted mainly in a few rich countries, squandering opportunities to improve the health of people globally.

STAT OpEd: Fecal transplants are saving lives — but are now at risk
By Neil Stollman, MD
Stollman is chief of the Division of Gastroenterology at the Alta Bates Summit Medical Center and works at the East Bay Center for Digestive Health, both in Oakland, California.
Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection. I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced.

Policy Outlook: Building a microbiome-informed approach to agri-food systems and childhood nutrition policies
A holistic, microbiome-informed approach to agrifood systems and childhood nutrition policies—rooted in global collaboration, evidence-building, and equitable innovation—can drive sustainable solutions to undernutrition and improve children’s health worldwide.
As Microbiome Science Forges Ahead, Will Some Be Left Behind?
The FDA’s approval of the first fecal microbiota treatment was a watershed moment — and also a wakeup call.
Letter from the CEO: The Road Ahead as the OpenBiome Foundation
Today, we are proud to share the next chapter of our journey: OpenBiome is becoming the OpenBiome Foundation. With this transition, we renew and refocus our commitment to accelerating microbiome science and ensuring its benefits reach those who need them most.

Boosting microbiome science worldwide could save millions of children’s lives
Boosting microbiome science worldwide could save millions of children’s lives.Studies of the microbes living on and in our bodies are conducted mainly in a few rich countries, squandering opportunities to improve the health of people globally.
AGA calls on FDA to Retain Access to Conventional FMT
In addition to the new FDA-approved therapies, we still need access to conventional fecal microbiota transplantation for complicated and vulnerable patients with C. diff infection.

OpenBiome Foundation Launches to Catalyze Breakthroughs in Microbiome Science

Science in the Field: Dr. Walter Sandoval’s Mission to Map Rural Microbiomes in Paraguay

Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.

From Stool Donation to FMT Preparation: The Logistics of FMT Manufacturing

When is an FMT Treatment Ready for Use? Health Monitoring and Material Release

Tracking Patient Outcomes and Adverse Events: Considerations for Pharmacovigilance

Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection













